Single-use Bioreactors Market Share, Size, Trends, Industry Analysis Report, By Product (Bioreactor Systems, Media Bags, Filtration Assemblies, Others); By Cell (Mammalian, Bacteria, Yeast, Others); By Molecule; End-Use; By Region; Segment Forecast, 2022 - 2030
- Published Date:Jan-2022
- Pages: 112
- Format: PDF
- Report ID: PM2206
- Base Year: 2021
- Historical Data: 2018 - 2020
Report Outlook
The global single-use bioreactors market was valued at USD 3.43 billion in 2021 and is expected to grow at a CAGR of 21.6% during the forecast period. The major propelling factors for the market growth are the advancements in cellular and molecular studies, and the applications and functionality of these bioreactors pan into various fields across medical research and analysis.
Know more about this report: request for sample pages
Also, ease in the cultivation of marine organisms, reduced automation complexity, and decreasing energy & water consumption are major catalytic factors for the market growth in the approaching years. The arrival of COVID-19 highly impacts various sectors in the global single-use bioreactors market as well as the economy. Implementing stringent government norms for social distancing and lockdowns in various regions considerably obstruct the supply chain, logistics & shipments, and production process due to the unavailability of the resources.
However, the rapid development of vaccines in response to the novel coronavirus treatment supports the growth of single-use bioreactors equipment and systems. Thereby, it may pave the way for industry growth. Numerous key manufacturers of single-use bioreactors are developing a vaccine against the coronavirus and are working with companies that have a vaccine already in the clinical test phases. Therefore, this coronavirus outbreak may bring an upsurge in the single-use bioreactors industry growth.
Know more about this report: request for sample pages
Industry Dynamics
Growth Drivers
The rising number of R&D activities in the biopharmaceutical field is spurring market demand across the globe. The increasing population is fueling demand for biopharmaceuticals, as people are more prone to suffering from a wide range of diseases. Thereby, the leading global competitors of the single-use bioreactors market are focusing on production and R&D of biopharmaceuticals for meeting the consumer rising demand. The biopharmaceutical sector invests a standard of six times higher in R&D activities as a percentage of sales are compared to further manufacturing sectors.
For instance, in 2018, the biopharmaceutical company invested around USD 102 Billion (expected) in R&D as per the PhRMA. Single-use bioreactors technologies play a fundamental role in biopharmaceutical manufacturing workflows. It creates a large proportion of small and mid-scale biopharmaceutical manufacturing, mainly in clinical testing and R&D. Therefore, the penetration of the single-use bioreactors systems is increased across the biopharmaceutical R&D as it offers various advantages in comparison to conventional bio-manufacturing. Therefore, the growing R&D spending is measured as a positive indicator for the demand for single-use bioreactors, which may fuel the industry's growth in the forthcoming scenario.
Report Segmentation
The market is primarily segmented on the basis of product, cell, molecule, end-use, and region.
|
By Product |
By Cell |
By Molecule |
By End-Use |
By Region |
|
|
|
|
|
Know more about this report: request for sample pages
Insight by Product
The single-use bioreactor systems segment is accounted for the largest revenue in the global market. These systems provide extensive benefits, including reduced investment and a lower environmental footprint, driving the adoption of such systems in biopharma applications. In addition, the numerous opportunities from the developing countries and an expected surge in biosimilars use in the U.S. are expected to boost the segment’s growth. For instance, as per PharmaManufacturing.com, around USD 110 Bn of biologics are projected to go off-patent by 2020. Therefore, with the rising pressure to mitigate the healthcare cost and monitoring clarity on biosimilar, the demand for a biosimilar is becoming a key factor for segmental growth across the globe.
Moreover, the single-use bioreactor segment is also expected to demonstrate the highest CAGR, owing to the robust growth of the strategic partnership between pharmaceutical and biopharmaceutical along with the end-user, along with the improvement in biopharma infrastructure across emerging nations are accelerating the segment growth over the approaching years.
Insight by End-Use
The pharmaceutical and biopharmaceutical industry segment is recorded with the largest shares in 2021 and is expected to lead the single-use bioreactors market in the forecasting years. The pharmaceutical and biopharmaceutical companies use single-use bioreactors in order to the rapid proliferation of disposable technology in the pharma and biopharma sector, cost-effectiveness, and increased government initiatives for biopharmaceutical research.
With the introduction of single-use bioreactors in the field of pharma and biopharma, its contribution has grown-up towards various applications such as bioproduction, research, process development. Thus, the growing demand for bioproduction and medical research is one of the major factors that drive the growth of this segment across the world. Moreover, the rising availability of government and private funding in the healthcare sector is another factor that impels the demand for single-use bioreactors among pharmaceuticals and biopharmaceutical companies.
The Contract Research Organization (CRO) segment is projected to be the fastest-growing segment during the forecast period. The rising outsourcing of R&D and manufacturing services by pharmaceutical and biopharmaceutical companies is projected to aid the growth of the CROs & CMOs segment. Further, several CROs are extensively involved in order to boost their service offering associated with single-use bioreactors. This enables their several advantages such as time-savings, overall cost-effectiveness, and delivery of efficient and desired results to the clients, which eventually boosts the segmental growth across the globe.
Geographic Overview
Geographically, North America is accounted with the highest revenue share in the global market in 2021 and is likely to dominate the market over the upcoming scenario. The established presence of the biopharmaceutical industry, along with the rise in the presence of advanced technologies, is likely to impel the single-use bioreactors market demand. Besides, DNA sequencing is the other critical area that compels the study of molecular, cellular, and DNA structures. These aforementioned factors are likely to strengthen sales across North America in the forthcoming years.
Moreover, Asia Pacific and Europe are also expected to contribute a significant share in the global market during the forthcoming years. Factors such as rising R&D activities in the biomedical industry, coupled with the robust demand for cleaning and sterilization subsequent to the use of bioreactors, are further fueling the market demand. Hence, it may positively influence the demand for a global market that creates lucrative opportunities in the near future.
Competitive Insight
Some of the major players operating in the global market include ABLE Corporation & Biott Corporation, BBI-Biotech GMBH, Cellexus, Celltainer Biotech BV, Cesco Bioengineering Co., Ltd., Danaher Corporation, Distek, Inc., Eppendorf AG, G&G Technologies, Inc., Getinge AB, Meissner Filtration Products, Inc., Merck Millipore, PBS Biotech, Inc., Sartorius AG, Solida Biotech GMBH, Stobbe Pharma GMBH, and Thermo Fisher Scientific Inc.
Single-use Bioreactors Market Report Scope
|
Report Attributes |
Details |
|
Market size value in 2021 |
USD 3.43 billion |
|
Revenue forecast in 2030 |
USD 17.97 billion |
|
CAGR |
21.6% from 2022 - 2030 |
|
Base year |
2021 |
|
Historical data |
2018 - 2020 |
|
Forecast period |
2022 - 2030 |
|
Quantitative units |
Revenue in USD million/billion and CAGR from 2022 to 2030 |
|
Segments covered |
By Product, By Cell, By Molecule, By End-Use, By Region |
|
Regional scope |
North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
|
Key companies |
ABLE Corporation & Biott Corporation, BBI-Biotech GMBH, Cellexus, Celltainer Biotech BV, Cesco Bioengineering Co., Ltd., Danaher Corporation, Distek, Inc., Eppendorf AG, G&G Technologies, Inc., Getinge AB, Meissner Filtration Products, Inc., Merck Millipore, PBS Biotech, Inc., Sartorius AG, Solida Biotech GMBH, Stobbe Pharma GMBH, and Thermo Fisher Scientific Inc. |
